Our Business Strategy

Serentis is a commercially focused, emerging biopharmaceutical company with a number of products in development in the area of dermatology.  It operates an outsourcing model and has an established network of research and development partners.

Our objective is to add maximum value to our projects by undertaking rapid and efficient product development.  Projects are sourced from both internal research and innovation, and from licensing and acquisitions in order to maintain a sustainable, risk-balanced product portfolio.

Internal research is focused on repositioning existing drugs and their templates in dermatological conditions.  Serentis optimises its products for targets indications via both chemical modification and reformulations.  This approach allows Serentis to establish clinical proof-of-principle early in the development of a project, and avoids the risk and cost associated with the initial development of new chemical entities.  Projects target dermatological conditions characterised by clear unmet need and validated biological targets.

Our partnering strategy is to license or acquire assets which are in, or close to, clinical development. We are actively looking for products and technologies, at this stage of development, with application in the area of dermatology.  If you are interested in partnering with Serentis, please contact Gunnar Staaf, Commercial Director.